Bumper Offer - Urjas oil Just @ Rs. 1
Zyrova 2 Tablet is a commercial drug that is prescribed in the form of Tablet. It is typically used for the treatment of High Cholesterol. Zyrova 2 Tablet also has some secondary and off-label uses. These are listed below.
The optimal dosage of Zyrova 2 Tablet is largely dependent on the individual's body weight, medical history, gender and age. The condition it has been prescribed for, and the route of administration also determine the right dosage. For detailed information on this, read through the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Zyrova 2 Tablet as well, which are listed below. Such side effects of Zyrova 2 Tablet normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Zyrova 2 Tablet has a Severe effect for pregnant women and Mild effect on lactating mothers. Warnings related to Zyrova 2 Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Zyrova 2 Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Zyrova 2 Tablet in conditions like Kidney Disease, Hypothyroidism, Drug Allergy. Other contraindications of Zyrova 2 Tablet have been discussed in the sections ahead.
Drug interactions for Zyrova 2 Tablet have been reported in the medical literature. See below for a complete list.
In addition to these precautions, you may also note that Zyrova 2 Tablet is safe while driving, and is is addictive in nature.
Zyrova 2 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Is the use of Zyrova 2 Tablet safe for pregnant women?
Pregnant women may get severe side effects after taking Zyrova. If you are pregnant, do not take Zyrova without a doctor's advice.
Is the use of Zyrova 2 Tablet safe during breastfeeding?
Zyrova has been seen to have minimal side effects on breastfeeding women.
What is the effect of Zyrova 2 Tablet on the Kidneys?
Zyrova can have moderate side effects on the kidney. If you notice any harmful effects, stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Zyrova 2 Tablet on the Liver?
You may experience side effects on your liver after taking Zyrova. If this happens, then discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Zyrova 2 Tablet on the Heart?
Zyrova is rarely harmful for the heart.
Zyrova 2 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Zyrova 2 Tablet unless your doctor advises you to do so -
Is this Zyrova 2 Tablet habit forming or addictive?
No, there is no any evidence that Zyrova 2 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Zyrova 2 Tablet does not cause dizziness or sleep, so you can drive a vehicle or operate machinery also.
Is it safe?
Yes, but consume Zyrova 2 Tablet only on doctor's advice.
Is it able to treat mental disorders?
Zyrova 2 Tablet is unable to treat or cure mental disorders.
Interaction between Food and Zyrova 2 Tablet
Some foods when eaten with Zyrova 2 Tablet can alter the onset of actions. Discuss this with your doctor.
Interaction between Alcohol and Zyrova 2 Tablet
Consuming Zyrova 2 Tablet with alcohol can have many serious effects on your body.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
